Literature DB >> 113868

Fluorescent anti-colonic and E. coli antibodies in ulcerative colitis.

H Marcussen.   

Abstract

With the indirect immunofluorescence technique using sections of colon from guenon and rat, sera from patients with ulcerative colitis yielded positive staining of goblet cells. Eight sera, thus defined positive, two negative, and five from hospital controls, were applied to agar preparations of 12 different E. coli strains, normally found in human bacterial diseases and E. coli 0 14. With E. coli 0 group antigens, 2, 8 and 14 positive fluorescence reactions were regularly found in sera where positive immunofluorescence reaction aginst colon antigen could be demonstrated, indicating that antigen(s) from colon mucosa shares antigenic determinant(s) with some E. coli bacteria or bacterial components.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 113868     DOI: 10.3109/00365527809179820

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  8 in total

1.  Detection of anti-colon antibodies in inflammatory bowel disease using human cultured colonic cells.

Authors:  J C Lee; A M Cevallos; A Naeem; J E Lennard-Jones; M J Farthing
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

2.  In vitro anticolon antibody production by mucosal or peripheral blood lymphocytes from patients with ulcerative colitis.

Authors:  T Hibi; M Ohara; K Toda; A Hara; H Ogata; Y Iwao; N Watanabe; M Watanabe; Y Hamada; K Kobayashi
Journal:  Gut       Date:  1990-12       Impact factor: 23.059

3.  Enzyme linked immunosorbent assay (ELISA) and immunoprecipitation studies on anti-goblet cell antibody using a mucin producing cell line in patients with inflammatory bowel disease.

Authors:  T Hibi; M Ohara; K Kobayashi; W R Brown; K Toda; H Takaishi; Y Hosoda; A Hayashi; Y Iwao; M Watanabe
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

4.  Circulating antibodies to the surface antigens on colon epithelial cells in ulcerative colitis.

Authors:  T Hibi; S Aiso; M Ishikawa; M Watanabe; T Yoshida; K Kobayashi; H Asakura; S Tsuru; M Tsuchiya
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

5.  Anti-colon antibody and lymphocytophilic antibody in ulcerative colitis.

Authors:  T Hibi; S Aiso; T Yoshida; M Watanabe; H Asakura; S Tsuru; M Tsuchiya
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

6.  pANCA represents a cross-reactivity to enteric bacterial antigens.

Authors:  F Seibold; S Brandwein; S Simpson; C Terhorst; C O Elson
Journal:  J Clin Immunol       Date:  1998-03       Impact factor: 8.317

7.  Interleukin 2 and interferon-gamma augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis.

Authors:  T Hibi; M Ohara; M Watanabe; T Kanai; H Takaishi; A Hayashi; Y Hosoda; H Ogata; Y Iwao; S Aiso
Journal:  Gut       Date:  1993-06       Impact factor: 23.059

8.  Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease.

Authors:  F Seibold; P Weber; H Jenss; K H Wiedmann
Journal:  Gut       Date:  1991-10       Impact factor: 23.059

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.